AJMC - The American Journal of Managed Care’s Post

September is Pulmonary Fibrosis Awareness Month, a time to shine a light on this serious lung disease that affects many Americans. Pulmonary fibrosis causes scarring in the lungs, making it difficult to breathe and limiting oxygen to vital organs. Early detection and support are critical. Let’s work together to raise awareness and support those affected. Learn more about the symptoms, treatment options, and how you can get involved in the fight against pulmonary fibrosis. Find information and resources here: https://lnkd.in/gw4gN8bH #PulmonaryFibrosis #LungHealth #AwarenessMatters

Some types can be relatively mild and slow-progressing, while others, like idiopathic pulmonary fibrosis, can be rapidly progressive and life-threatening. https://bit.ly/45iorye

Tackling Calcium in Peripheral Vascular Disease with IVL Webinar with Shockwave TONIGHT AT 7PM Join our expert panel to explore current issues and challenges in calcification and see how IVL can play a crucial role in improving outcomes for patients. Learn from case studies, discover tips and tricks to optimize outcomes and join the discussion. Duration: 2 hours Price: Free 🔗 Book via the link in the comments

Dear cardiometabolic specialists, Our full slide deck on the ZENITH-CKD trial from Heerspink et al. is now live on the CMF! Access this free resource now to gain insights on the combination therapy of Zibotentan and Dapagliflozin in patients with chronic kidney disease: https://lnkd.in/eje5_Va4

Pulmonary Fibrosis: Challenges in Diagnosis, Treatment and Management 🫁 🏥 Pulmonary fibrosis (PF) is a progressive lung disease characterised by fibrosis or scarring of the lung tissue. As the disease progresses the build-up of fibrotic tissue causes the lungs to stiffen, limiting their ability to expand and contract, resulting in declines in lung function. By far the most common type of PF is idiopathic pulmonary fibrosis (IPF), which describes PF cases for which no cause has been established. According to recent estimates, there may be around 30,000 people in the UK currently living with IPF... Explore our latest blog via the links in the comments! ⬇️ #pulmonaryfibrosis #pulmonary #healthtech

Have you seen this webinar? 👀 More than 22,000 people in the PF community have tuned in to learn about progressive pulmonary fibrosis (PPF). Dr. Anna Podolanczuk is an internationally recognized expert in interstitial lung disease, and in this full-length webinar, she dives in to what you need to know about this form of pulmonary fibrosis. https://lnkd.in/gbwWjjeX

INSIDE LOOK 👀 Read more of the latest research from the upcoming issue (September 9): Is the achievement of sputum culture conversion in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) and cavitary lesions associated with the prognosis? Read the full original research in the September issue to learn more: https://hubs.ly/Q02NR5wG0 #MedEd #JournalCHEST

Time to diagnosis is the first major hurdle for those with pulmonary fibrosis. Many go un- or misdiagnosed for YEARS. Even as long as 5 or 10 years, or more. Yet "time" is critical for those living with PF. "Time" can: -- Be the difference between having a chance at extending life expectancy with one of the two approved antifibrotics or not having antifibrotic treatment available -- Allow for finding the cause of PF (if not IPF - idiopathic PF: PF with no known cause) and treating that cause in an attempt to slow progression of PF -- Allow for educating patients and their loved ones about better self care and minimizing or removing those things in their lifestyle or environment that might further progression of their PF -- Give patients and their loved ones more time to prepare for what's coming; emotionally, financially, personally (allowing for filling those "bucket list" items) Time to diagnosis can be everything to someone living with PF. Help reduce time to diagnosis by sharing this great infographic provided by Chest and Three Lakes Foundation and also find the very best in pulmonary fibrosis education and support through the Breathe Support Network at www.BreatheSupport.org. https://lnkd.in/g7sQk2Qb #LIVEwithPF #timetoPFdiagnosis #pulmonaryfibrosis #BreatheSupport

Cardiologist Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the limitations and challenges within pulmonary arterial hypertension (PAH) treatment strategies, including the adoption of new therapies and the impact of emerging treatments on patient outcomes, quality of life, and long-term disease management. Watch the episode to learn more about the future of PAH: https://bit.ly/4be1QWh #hypertension

Knowing the signs and early intervention is key to accessing early interventions that can reduce disease progression #pulmonaryfibrosis